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Abstract
To clarify the significance of immunoglobulin G autoantibody specific for the
astrocyte water channel aquaporin-4 in cerebrospinal fluid, aquaporin-4-immu-
noglobulin G from a neuromyelitis optica patient was administered intrathe-
cally to na€ıve mice, and the distribution and pathogenic impact was evaluated.
A distinct distribution pattern of aquaporin-4-immunoglobulin G deposition
was observed in the subarachnoid and subpial spaces where vessels penetrate
the brain parenchyma, via a paravascular route with intraparenchymal perivas-
cular deposition. Perivascular astrocyte-destructive lesions were associated with
blood-borne horseradish peroxidase leakage indicating blood-brain barrier
breakdown. The cerebrospinal fluid aquaporin-4-immunoglobulin G therefore
distributes widely in brain to initiate astrocytopathy and blood-brain barrier
breakdown.
Introduction
Neuromyelitis optica (NMO) is an autoimmune inflam-
matory disease of the central nervous system (CNS),1
associated with serum immunoglobulin G autoantibody
specific for water channel aquaporin-4 (AQP4-IgG).2
AQP4-IgG is thought to mediate pathogenesis by binding
selectively to AQP4 on astrocytes, causing complement-
dependent injury.3 AQP4 is densely localized on ependy-
mal cells and astrocytes, forming the glia limitans of the
blood-brain barrier (BBB).2 Ependymal cells do not have
a basement membrane and do not express tight junctions,
thus AQP4-IgG in the cerebrospinal fluid (CSF) would
have relatively free access to their target.4 AQP4-IgG is
pathogenic only when reaching the CNS parenchyma as
demonstrated in experimental animals where direct
administration of AQP4-IgG into the CNS or with prees-
tablished CNS inflammation induced NMO-like histopa-
thology, whereas peripheral administration into na€ıve
animals had no effect.5 NMO patients can be AQP4-IgG
positive in serum for many years prior to the onset of
disease.6,7 Gadolinium-enhanced magnetic resonance
imaging (MRI) shows acute lesions in CNS including
meningeal enhancement and markers of BBB permeability
are significantly elevated during disease activity indicating
BBB dysfunction.8,9 NMO lesions often have association
to blood vessels as though the pathogenic mediator
entered from blood.3 AQP4-IgG is detectable in the CSF
of most AQP4-IgG seropositive NMO patients with
AQP4-IgG serum titers >1:250 during acute disease
relapse.10 Since intrathecal IgG synthesis in NMO only
occurs rarely and does not persist over time, CSF AQP4-
IgG likely derives from serum, but how it contributes to
pathogenesis and BBB breakdown is poorly understood.1
We have previously reported that intrathecal injection
of AQP4-IgG together with complement into the CSF of
mice induced NMO-like periventricular lesions, correlat-
ing with ependymal damage.11 We also observed paren-
chymal NMO-like lesions that did not always co-localize
with ependymal damage, suggesting entry by other route
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AQP4-IgG or control human IgG (HuIgG) and human
complement were prepared as described11 and adminis-
tered to adult female C57BL/6 mice as a single injection
(6 lL AQP4-IgG + 4 lL complement) into CSF at the
cisterna magna.11 Mice were sacrificed after 2 days.
The use of human material was approved by The Com-
mittee on Biomedical Research Ethics for the Region of
Southern Denmark (ref. no. S-20080142). Mice were
housed and experiments performed in accordance with
the Danish Animal Research Committee (approval num-
ber 201215293400110).
Tissue processing, histochemistry and
immunohistochemistry
Tissue preparations were made.11 BBB breakdown was
examined by injecting horseradish peroxidase (HRP) as a
tracer intravenously 15 min before perfusion, then stain-
ing in tissue. Mouse IgG was detected by HRP-conjugated
goat anti-mouse-IgG (A4416; Sigma, Sigma-Aldrich,
Brøndby, Denmark). Single and double immunostaining
were performed as described.11
Histopathology
Evaluation of histological changes was performed in a
blinded manner and semiquantitatively using a scale from
0 to 3 (+ to +++) as described.11 Results were analyzed by
one-way analysis of variance (ANOVA) test and Mann–
Whitney U-Test. A P < 0.05 was considered statistically
significant.
Animal assessment
Animals were assessed by measurement of whole body
weight and gross evaluation of well-being. Assessment of
behavioral or motor changes was not part of the study
design. There was no difference between body weight of
mice that received AQP4-IgG + complement and controls.
Results
Entry of AQP4-IgG from CSF into the brain
parenchyma
We examined parenchymal distribution patterns of
AQP4-IgG in brain parenchyma and pathologic effects,
following intrathecal injection. Injection of AQP4-
IgG + complement into the CSF was followed by deposi-
tion of HuIgG along the subarachnoid space and the sub-
pial spaces where vessels penetrate the brain parenchyma
in 8/14 mice, severe in five, localized in the cerebellum,
brainstem and to a lesser degree in the cortex (Fig. 1A–E
and J). This deposition was for AQP4-IgG + complement
associated with an intense perivascular deposition at brain
parenchymal vessels distal from the site of parenchymal
entry of pial vessels (Fig. 1F, G, and K) in five mice. In
this area no deposition was observed for control HuIgG
(0/10), and apart from one animal (1/12) with a moder-
ate score in the cerebellum, AQP4-IgG deposition was
only notable when co-injected with complement. For sites
close to the brain surface where pial vessels penetrate
there was some deposition of AQP4-IgG alone (6/12) and
of control IgG + complement (6/13) and – complement
(5/10) in the cerebellum.
In addition, AQP4-IgG from CSF was distributed to
the periventricular region as described previously11
(Fig. 1H, I, and L). Co-injection of complement led to
intense deposition in three mice and IgG deposition in 8/
14 mice. Deposition was most intense at the fourth and
lateral ventricles. AQP4-IgG alone (deposition in 8/12)
Figure 1. Distribution of AQP4-IgG from cerebrospinal fluid (CSF) into the brain parenchyma. (A) Subpial vasculature in relation to subarachnoid
space and brain parenchyma, showing relevant anatomical structures including the pial vessel, subarachnoid space, the Virchow-Robin space and
the subpial glia limitans surrounding penetrating vessels into the brain, in schematic form. (B) A mouse brain in sagittal section showing a
diagram of the intrathecal distribution of human IgG in this study. Areas of penetrating vessels into the brain are marked with rectangles. (C–K)
Sagittal sections of the brain of animals after intrathecal injection of AQP4-IgG + complement into the cisterna magna. Sections were stained for
human IgG. (C) Micrographs show distribution of AQP4-IgG in the brain parenchyma around surface pial vessels in subarachnoid and subpial
spaces, surrounding penetrating vessels into the brain in midbrain (superior colliculus, midbrain), (D) and in a cortical region proximal to the
hippocampus, (E) shows a magnified view of an area in (D) with a penetrating vessel into the brain. (F) Perivascular deposition of AQP4-IgG at
brain parenchymal vessels distal from the site of parenchymal entry of pial vessels in cerebellum and (G) midbrain. (H) periventricular deposition of
AQP4-IgG at the lateral ventricles and (I) Magnified view of an area from (H). (J–L) HuIgG deposition of varying intensity from groups of mice
treated 2 days previously by intrathecal injection of AQP4-IgG + complement (n = 14), AQP4-IgG alone (n = 12), control HuIgG (n = 10), control
HuIgG + complement (n = 13). Histological grading as mild (+ = 1), moderate (++ = 2) or intense (+++ = 3). Data are presented as mean  SD,
(J) Paravascular route deposition (K) Perivascular deposition at brain parenchymal vessels distant from the site of parenchymal entry of pial vessels
(L) Periventricular deposition. Bar 50 lm (C, F, and G), 20 lm (inserts F, G, and E), 100 lm (D and I), 200 lm (H).
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and control IgG (6/10) distributed similarly, localized at
the fourth ventricle, and deposition of control IgG was
not influenced by complement (6/13).
The distribution patterns J and L did not show any
significant difference between the groups. AQP4-IgG +
complement-treated mice presented a significantly more
intense perivascular deposition of HuIgG (pattern K) as
compared to controls HuIgG and HuIgG + complement
(P < 0.0001). These data indicate that pattern K is spe-
cific for AQP4-IgG.
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AQP4-IgG in the CSF induces perivascular
astrocyte-destructive lesions
The perivascular deposition of HuIgG, observed at brain
parenchymal vessels distant from the site of pial vessels in
mice that received AQP4-IgG + complement, raised the
question whether AQP4-IgG would achieve sufficient
concentrations at brain parenchymal vessels to initiate
astrocyte-destructive lesions. Perivascular leakage of HuIgG
co-localized with deposition of C9neo (a marker of the
membrane attack complex, i.e., activated complement) and
astrocytopathy (loss of AQP4 and glial fibrillary acidic
Figure 2. AQP4-IgG in the CSF induces perivascular complement-dependent astrocyte injury. Micrographs show sagittal sections of the brain of
animals that had received intrathecal injection of AQP4-IgG + complement (A–F) or control IgG + complement (G–I). Sections were stained for AQP4
(A, D, and G), GFAP (B, E, H, and K) and C9neo (J). Areas of histopathological changes are marked with white arrowheads. (A and B) Loss of AQP4, (D
and E) Loss of GFAP staining in midbrain and in cerebellum. This astropathy coincided with perivascular deposition of HuIgG at brain parenchymal
vessels distant from the site of pial vessels in mice that received AQP4-IgG + complement. (C and F) Merge of (A and B), and (D and E) respectively,
showing that loss of AQP4 coincided with loss of GFAP. Such pathology was not seen in control mice (G–I). (J–L) Deposition of C9neo at the same
locations as loss of AQP4 and GFAP, denoted by white arrows. (M and N) Semi-quantitative estimate of loss of AQP4 (M) and GFAP immunoreactivity.
Data are presented as mean  SD (N). Bar 15 lm (J–L), Bar 20 lm (A–I). CSF, cerebrospinal fluid; GFAP, glial fibrillary acidic protein.
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protein [GFAP]) in the five AQP4-IgG + complement-trea-
ted mice, with perivascular and subpial deposition of HuIgG
in cerebellum (+++), brainstem (++) and to a lesser degree
in cortex (+) (Fig. 2A–F and M, N). In addition, similar
NMO-like lesions were induced by AQP4-IgG + comple-
ment in subpial space and surrounding the ventricular sys-
tem as described previously.11 These histopathological
changes were not seen in control mice (Fig. 2G–I).
Effects of intrathecal AQP4-IgG on the
integrity of the BBB
Perivascular astrocyte-destructive lesions were associated
with disruption of the BBB. HRP from peripheral
blood leaked into the brain parenchyma in cerebellum
and brainstem and to a lesser degree in cortex in the
same five AQP4-IgG + complement-treated mice that
exhibited perivascular astrocyte pathology (5/14)
(Fig. 3A–G). Staining for mouse IgG confirmed the
HRP results, and verified that parenchymal diffusion of
CSF-derived control HuIgG was not accompanied by
endogenous mouse IgG (data not shown). BBB break-
down without AQP4-IgG-mediated immunopathology
was not observed.
In the control group one mouse receiving AQP4-IgG
alone (1/12) showed faint HRP staining in the cerebellum.
The HRP staining in the brain was not seen in control
mice (Fig. 3H and I).
Figure 3. BBB breakdown associates with CSF-derived AQP4-IgG + complement and perivascular astrocyte pathology. Micrographs show sagittal
sections of the brain of animals injected with AQP4-IgG + complement. BBB breakdown was visualized by leakage of intravenously injected HRP
as tracer (brown). (A–F) Micrographs show HRP leakage into the brain parenchyma in cerebellum and midbrain, (D) shows a magnified view of an
area in (C) in midbrain. (B and E) show magnified views of perivascular HRP leakage shown in (A and C) respectively, as wide halos around blood
vessels. Such pathology was not seen in controls mice (H and I). (G) Quantitation of HRP leakage into the brain parenchyma in animals injected
with AQP4-IgG + complement (n = 14), AQP4-IgG alone (n = 12), control HuIgG (n = 10), control HuIgG + complement (n = 13), expressed on a
scale of 0–3. Data are presented as mean  SD. Data indicate BBB breakdown in AQP4-IgG + complement-treated mice. Bar 50 lm (B and D),
20 lm (E), 100 lm (A and F), 200 lm (C, F, and H). BBB, blood-brain barrier; CSF, cerebrospinal fluid; HRP, horseradish peroxidase.
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Discussion
In this study the anatomical basis of distribution of IgG
from CSF to brain parenchyma was investigated. A spe-
cific distribution pattern of AQP4-IgG was identified
along subarachnoid and subpial spaces, where vessels pen-
etrate the brain parenchyma, with pronounced intrapa-
renchymal perivascular deposition compared to control
IgG. These changes were accompanied by perivascular
astrocyte-destructive lesions and by leakage of the blood-
derived tracer HRP and serum-IgG into brain paren-
chyma, reflecting BBB breakdown.
The subpial space surrounds penetrating vessels,12 and
is completely ensheathed by astrocyte end-feet. The pial
cell layer is fenestrated at the level of the arterioles and
widely lacking at the level of capillaries and venules.13 In
these areas, the AQP4-expressing astrocytic endfeet are
directly exposed to CSF AQP4-IgG. Recently, an anatomi-
cally distinct clearing system in the brain was described,
whereby a large proportion of subarachnoid CSF circu-
lates through the brain parenchyma via the so-called
paravascular route and is exchanged with the interstitial
fluid.14 This observation was substantiated by studies in
which fluorescent tracers and a MRI contrast agent could
be tracked from CSF to brain parenchyma via this
route.15 This pathway comprises a physically and func-
tionally distinct sub-compartment of the brain circula-
tion. Interestingly, the glia limitans-associated water
pump AQP4 drove the flow of fluid along this route and
through the interstitium.15 Consistent with these observa-
tions our data suggest that AQP4-IgG in CSF can achieve
widespread distribution within the brain via this paravas-
cular pathway to exert pathologic effects by selective
binding to astrocytes with subsequent complement-
dependent cytotoxicity that includes parenchymal BBB
disruption.
For several reasons not all mice showed the same dis-
tribution of pathology. Firstly, we intrathecally injected
only a single bolus of AQP4-IgG plus complement. Sec-
ondly, recirculation of the CSF may lead to a further dilu-
tion of the preparation. Thirdly, only a proportion of the
subarachnoid CSF enters the brain parenchyma along
paravascular channels surrounding penetrating arteries.
Furthermore, astrocytopathy and BBB disruption require
even deeper penetration of IgG distant from the site of
parenchymal entry of pial vessels.
In NMO the presence and levels of AQP4-IgG in CSF
are associated with high titers of AQP4-IgG in serum dur-
ing disease attacks.10,16,17 Moreover, the amount of AQP4-
IgG present in the CSF correlated with astrocyte damage,
as reflected in elevated levels of GFAP in the CSF during
relapse of NMO18 and BBB disruption.17,19 In the present
study AQP4-IgG in CSF was observed to be a critical
element to promote perivascular astrocyte pathology and
consequently BBB disruption. These data suggest a model
whereby a small amount of AQP4-IgG initially is spilled
over to the CSF, and then initiates a pathogenic process,20
similar to the characteristic CSF data and radiological fea-
tures of human NMO.8,17,21 This model may be further
improved by repetitive administration of antibody.22
In conclusion we have utilized an intrathecal route for
antibody administration, mimicking physiological pres-
ence of antibody in the CSF. We demonstrate that
AQP4-IgG in CSF achieves widespread distribution to
brain parenchyma via the paravascular route. Our obser-
vations that perivascular astrocyte-destructive lesions are
formed in the brain parenchymal vessels associated with
inside-out breakdown of the BBB indicate that AQP4-
IgG in CSF can be a significant element in NMO patho-
genicity.
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